Germany - Provision of personnel including temporary agency staff - Temporary staffing in the IT and infrastructure area

DAK-Gesundheit procured temporary agency workers to support its IT organisation with specialist, technical and organisational tasks. The service covered the provision of qualified staff under temporary employment arrangements and was divided into five lots: development of input management, development of output management and form development, further functional development of input and output management, network and telecommunications, and other IT operations topics. The procurement took place in Germany. The notice was open for bids until the deadline of 1 September 2026, and the tender is now closed for bids, so no further offers can be submitted.

Description

173 open tenders right now

• Health and social services - Workplace health promotion nutrition services 29 Sep 2026 · 5 days left
• Medical software package - Software for hospital invoice auditing 5 Oct 2026 · 11 days left
• E-bike and EV charging stations 5 Oct 2026 · 11 days left

Recent awards

• Medicines - Conclusion of a non-exclusive rebate agreement under § 130a paragraph 8 SGB V for the active ingredient Tacrolimus, ATC L04AD02, for 01.09.2024 - 31.08.2025 (plus extension option 1x12 months)

  awarded to 1 0 1 Carefarm GmbH; Aaragon Pharma s.r.o; Abacus Medicine A/S; ACA Müller ADAG Pharma AG; ALIUD PHARMA GmbH; Astellas Pharma GmbH; axicorp Pharma B.V.; CC Pharma GmbH; Chiesi GmbH; EMRA-MED Arzneimittel GmbH; EurimPharm Arzneimittel GmbH; Heumann Pharma GmbH & Co. Generica KG; kohlpharma GmbH; Orif

• Medicines - Non-exclusive rebate agreement under § 130a paragraph 8 SGB V for the active ingredient Ranibizumab, ATC S01LA04 for the period 01.09.2024 - 31.08.2026

  awarded to axicorp Pharma B.V.; kohlpharma GmbH; Originalis B.V.; 1 0 1 Carefarm GmbH; Abacus Medicine A/S; EurimPharm Arzneimittel GmbH; Medicopharm AG; Orifarm GmbH; 2care4 Aps; Aaragon Pharma s.r.o; Allomedic GmbH; Biogen GmbH; Novartis Pharma GmbH; STADApharm GmbH; Hexal AG; ratiopharm GmbH; Samsung Bioepi

• Medicines - Conclusion of a non-exclusive rebate agreement under Section 130a(8) SGB V for the active substance Triptorelin, ATC L02AE04, for the period 01.09.2024 - 31.08.2026

  awarded to axicorp Pharma B.V.; CC Pharma GmbH; EMRA-MED Arzneimittel GmbH; EurimPharm Arzneimittel GmbH; kohlpharma GmbH; Orifarm GmbH; Originalis B.V.; Ipsen Pharma GmbH

Market context

Avg. open tender · Business services

€23,476,051

5,929 open across Europe right now

Buyer track record on Aperlena

346 notices tracked · 131 awarded

€69,640,016 in awarded contracts